Suramin protects from cisplatin-induced acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 310, Issue 3, 2016, Pages F248-F258

  Dupre, Tess V ^a   Doll, Mark A ^a   Shah, Parag P ^a   Sharp, Cierra N ^a   Kiefer, Alex ^a   Scherzer, Michael T ^a   Saurabh, Kumar ^a   Saforo, Doug ^a   Siow, Deanna ^a   Casson, Lavona ^a   Arteel, Gavin E ^a   Jenson, Alfred Bennett ^b   Megyesi, Judit ^c   Schnellmann, Rick G ^d   Beverly, Levi J ^a,b   Siskind, Leah J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Cisplatin; Renoprotective strategies; Suramin

Indexed keywords

CASPASE 3; CASPASE 8; CISPLATIN; CREATININE; CXCL1 CHEMOKINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 1BETA; INTERLEUKIN 6; K RAS PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STRESS ACTIVATED PROTEIN KINASE; SURAMIN; TUMOR NECROSIS FACTOR ALPHA; CHEMOKINE; CYTOKINE; PROTECTIVE AGENT;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA DAMAGE; DOSE RESPONSE; DRUG MEGADOSE; ENDOPLASMIC RETICULUM STRESS; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY FUNCTION; LUNG ADENOCARCINOMA; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; TUNEL ASSAY; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CELL PROTECTION; CELL SURVIVAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; KIDNEY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ACUTE KIDNEY INJURY; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINES; CISPLATIN; CYTOKINES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM STRESS; KIDNEY; LUNG NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTECTIVE AGENTS; SURAMIN;

EID: 84956897995     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00433.2015     Document Type: Article

References (46)

1. Akcay A, Nguyen Q, He Z, Turkmen K, Won Lee D, Hernando AA, Altmann C, Toker A, Pacic A, Ljubanovic DG, Jani A, Faubel S, Edelstein CL. IL-33 exacerbates acute kidney injury. J Am Soc Nephrol 22: 2057-2067, 2011.
2. Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 25: 920-926, 1997.
3. Bailey MA, Imbert-Teboul M, Turner C, Srai SK, Burnstock G, Unwin RJ. Evidence for basolateral P2Y6 receptors along the rat proximal tubule: functional and molecular characterization. J Am Soc Nephrol 12: 1640-1647, 2001.
4. Braganhol E, Kukulski F, Levesque SA, Fausther M, Lavoie EG, Zanotto-Filho A, Bergamin LS, Pelletier J, Bahrami F, Ben Yebdri F, Fonseca Moreira JC, Battastini AM, Sevigny J. Nucleotide receptors control IL-8/CXCL8 and MCP-1/CCL2 secretions as well as proliferation in human glioma cells. Biochim Biophys Acta 1852: 120-130, 2015.
5. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15: 362-374, 2015.
6. Chahinian AP, Mandeli JP, Gluck H, Naim H, Teirstein AS, Holland JF. Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. J Surg Oncol 67: 104-111, 1998.
7. Chen J, Zhao Y, Liu Y. The role of nucleotides and purinergic signaling in apoptotic cell clearance-implications for chronic inflammatory diseases. Front Immunol 5: 656, 2014.
8. Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol 23: 547-555, 2013.
9. Choie DD, del Campo AA, Guarino AM. Subcellular localization of cis-dichlorodiammineplatinum(II) in rat kidney and liver. Toxicol Appl Pharmacol 55: 245-252, 1980.
10. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93-130, 2001.
11. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 27: 6245-6251, 2008.
12. Eichhorst ST, Krueger A, Muerkoster S, Fas SC, Golks A, Gruetzner U, Schubert L, Opelz C, Bilzer M, Gerbes AL, Krammer PH. Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med 10: 602-609, 2004.
13. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatininduced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322: 8-15, 2007.
14. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262, 2001.
15. Ganapaty S, Chandrashekhar VM, Narsu ML. Evaluation of antiallergic activity of gossypin and suramin in mast cell-mediated allergy model. Indian J Biochem Biophys 47: 90-95, 2010.
16. Grbic DM, Degagne E, Larrivee JF, Bilodeau MS, Vinette V, Arguin G, Stankova J, Gendron FP. P2Y6 receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells. Inflamm Bowel Dis 18: 1456-1469, 2012.
17. Hoyle CH, Knight GE, Burnstock G. Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guineapig urinary bladder and taenia coli. Br J Pharmacol 99: 617-621, 1990.
18. Korrapati MC, Howell LA, Shaner BE, Megyesi JK, Siskind LJ, Schnellmann RG. Suramin: a potential therapy for diabetic nephropathy. PLos One 8: e73655, 2013.
19. Korrapati MC, Shaner BE, Neely BA, Alge JL, Arthur JM, Schnellmann RG. Diabetes-induced renal injury in rats is attenuated by suramin. J Pharmacol Exp Ther 343: 34-43, 2012.
20. Korrapati MC, Shaner BE, Schnellmann RG. Recovery from glycerolinduced acute kidney injury is accelerated by suramin. J Pharmacol Exp Ther 341: 126-136, 2012.
21. Lange RC, Spencer RP, Harder HC. Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum II. J Nucl Med 13: 328-330, 1972.
22. Lieberthal W, Triaca V, Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol Renal Fluid Electrolyte Physiol 270: F700-F708, 1996.
23. Liu N, He S, Tolbert E, Gong R, Bayliss G, Zhuang S. Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLos One 7: e36194, 2012.
24. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, Zhuang S. Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22: 1064-1075, 2011.
25. Liu N, Tolbert E, Ponnusamy M, Yan H, Zhuang S. Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 338: 758-766, 2011.
26. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2: 2490-2518, 2010.
27. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int 2014: 967826, 2014.
28. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
29. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110: 835-842, 2002.
30. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285: F610-F618, 2003.
31. Safarinejad MR. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol 23: 93-101, 2005.
32. Shah PP, Beverly LJ. Regulation of VCP/p97 demonstrates the critical balance between cell death and epithelial-mesenchymal transition (EMT) downstream of ER stress. Oncotarget 6: 17725-17737, 2015.
33. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
34. Stallons LJ, Whitaker RM, Schnellmann RG. Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis. Toxicol Lett 224: 326-332, 2014.
35. Stathem M, Marimuthu S, O’Neal J, Rathmell JC, Chesney JA, Beverly LJ, Siskind LJ. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. J Cell Biochem 116: 67-80, 2015.
36. Stokes L, Surprenant A. Purinergic P2Y2 receptors induce increased MCP-1/CCL2 synthesis and release from rat alveolar and peritoneal macrophages. J Immunol 179: 6016-6023, 2007.
37. Summers SA, Chan J, Gan PY, Dewage L, Nozaki Y, Steinmetz OM, Nikolic-Paterson DJ, Kitching AR, Holdsworth SR. Mast cells mediate acute kidney injury through the production of TNF. J Am Soc Nephrol 22: 2226-2236, 2011.
38. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14: 1-10, 2003.
39. Unwin RJ, Bailey MA, Burnstock G. Purinergic signaling along the renal tubule: the current state of play. News Physiol Sci 18: 237-241, 2003.
40. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287: 664-666, 2000.
41. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of nonapoptotic cell death pathways. Nat Rev Mol Cell Biol 15: 135-147, 2014.
42. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. A Phase II trial of suramin monthly ´ 3 for hormone-refractory prostate carcinoma. Cancer 100: 65-71, 2004.
43. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 334: 115-124, 2007.
44. Zhang P, He JB, Ou LW, Wang XH. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. Ai Zheng 25: 409-413, 2006.
45. Zhuang S, Lu B, Daubert RA, Chavin KD, Wang L, Schnellmann RG. Suramin promotes recovery from renal ischemia/reperfusion injury in mice. Kidney Int 75: 304-311, 2009.
46. Zhuang S, Schnellmann RG. Suramin promotes proliferation and scattering of renal epithelial cells. J Pharmacol Exp Ther 314: 383-390, 2005.